Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3631-3640

  Toblli, Jorge E ^a   Cao, Gabriel ^a   Olivieri, Leda ^a   Angerosa, Margarita ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anaemia; Chronic kidney disease; Intravenous iron; Oxidative stress; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; IRON DEXTRAN; ISOTONIC SOLUTION; MALONALDEHYDE; SODIUM CHLORIDE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; IRON; IRON DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; FEMALE; HEART HOMOGENATE; HEMODYNAMIC PARAMETERS; HOMOGENATE; IRON BLOOD LEVEL; KIDNEY HOMOGENATE; LIVER HOMOGENATE; LIVER TOXICITY; MALE; MOLECULAR WEIGHT; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRANSFERRIN BLOOD LEVEL; URINARY EXCRETION; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; HEART; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; OXIDATIVE STRESS; SPRAGUE DAWLEY RAT; SYSTOLE;

ANIMALS; FEMALE; HEART; INJECTIONS, INTRAVENOUS; IRON; IRON COMPOUNDS; KIDNEY; LIVER; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE;

EID: 79952200956     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq260     Document Type: Article

References (49)

1. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69: S18-S21 (Pubitemid 29113579)
2. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37: S182-S238
3. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: Ii1-ii47
4. Macdougall IC, Chandler G, Armstrong A et al. Characterisation of iron availability from three different i.v. iron preparations in dialysis patients. J Am Soc Nephrol 1997; 8: 221
5. Anirban G, Kohli HS, Jha Vet al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail 2008; 30: 629-638
6. Macdougall I. Intravenous administration of iron in epoetin-Treated haemodialysis patients - which drugs, which regimen? Nephrol Dial Transplant 2000; 15: 1743-1745
7. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. 1992; 42: 1439-1452
8. Ternes N, Scheiber-Mojdehkar B, Landgraf G et al. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant 2007; 22: 2824-2830 (Pubitemid 350093433)
9. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991 (Pubitemid 33022176)
10. Zanen AL, Adriaansen HJ, van Bommel EFH et al. 'Oversaturation' of transferrin after intravenous ferric gluconate (FerrIecitR) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
11. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: A review. Nutrition 1995; 11: 163-168
12. Chertow GM, Mason PD, Vaage-Nilsen O et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-1575 (Pubitemid 38796422)
13. Bailie GR, Clark JA, Lane CE et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449 (Pubitemid 41430619)
14. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33: 464-470
15. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose - A review of its use in iron deficiency anaemia. Drugs 2009; 69: 739-756
16. Tagboto S, Cropper L, Turner J et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject®) on anaemia in a predialysis population of chronic kidney disease patients. J Ren Care 2009; 35: 18-23
17. Gordon SS, Hadley PE, Van Wyck DB et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding. Obstet Gynecol 2007; 109: 108S
18. Breymann C, Gliga F, Bejenariu C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73
19. Seid MH, Derman RJ, Baker JB et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435.e1-435.e7
20. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial. Obstet Gynecol 2007; 110: 267-278 (Pubitemid 47356650)
21. Toblli JE, Stella I, de Cavanagh E et al. Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Hypertension 1999; 33: 225-231 (Pubitemid 29065664)
22. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 1981; 77: 373-382
23. Rossi R, Cardaioli E, Scaloni A et al. Thiol groups in proteins as endogenous reductants to determine glutathione-protein mixed disulphides in biological systems. Biochim Biophys Acta 1995; 1243: 230-238
24. Auerbach M, Witt D, Toler W et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570
25. Kumpf VJ, Holland EG. Parenteral iron dextran therapy. DICP 1990; 24: 162-166 (Pubitemid 20105802)
26. Agarwal R, Rizkala AR, Bastani B et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26: 445-454 (Pubitemid 44971735)
27. Sav T, Tokgoz B, Sipahioglu MH et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29: 423-426 (Pubitemid 46752324)
28. Toblli JE, Cao G, Olivieri L et al. Inflammatory response of generic iron sucrose complex preparations in kidney, liver and heart of normal rats. Nephrol Dial Trans 2006; 21: Iv160
29. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41: S18-S26 (Pubitemid 36637965)
30. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-565 (Pubitemid 38263113)
31. Canavese C, Bergamo D, Ciccone G et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1564-1570 (Pubitemid 38786752)
32. Schiesser D, Binet I, Tsinalis D et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2841-2845 (Pubitemid 44542240)
33. Pardo Andreu GL, Inada NM, Vercesi AE et al. Uncoupling and oxidative stress in liver mitochondria isolated from rats with acute iron overload. Arch Toxicol 2008; 83: 47-53
34. Maher P, Lewerenz J, Lozano C et al. A novel approach to enhancing cellular glutathione levels. J Neurochem 2008; 107: 690-700
35. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534-554
36. Lim P-S, Wei Y-H, Yu YL et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687 (Pubitemid 32208386)
37. Crichton R, Danielson B, Geisser P. Iron Therapy with Special Emphasis on Intravenous Administration. 4th edition. London, Boston: International Medical Publishers; 2008.
38. Kulnigg S, Stoinov S, Simanenkov Vet al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192 (Pubitemid 351677967)
39. Youdim MB, Ben Schachar D, Riederer P. The possible role of iron in the etiiopathology of Parkinson's disease. Mov Disord 1993; 8: 1-2
40. Watanabe K, Yamashita Y, Ohgawara H et al. Iron content of rat serum ferritin. J Vet Med Sci 2001; 63: 587-589 (Pubitemid 33641142)
41. Bomford A, Conlon-Hollingshead C, Munro HN. Adaptive responses of rat tissue isoferritins to iron administration. Changes in subunit synthesis, isoferritin abundance, and capacity for iron storage. J Biol Chem 1981; 256: 948-955 (Pubitemid 11103053)
42. Linder MC, Moor JR, Munro HN. Subunit heterogeneity in rat liver apoferritin. Differential response of the subunits to iron administration. Biochim Biophys Acta 1974; 297: 70-80
43. Cragg SJ, Wagstaff M, Worwood M. Detection of a glycosylated subunit in human serum ferritin. Biochem J 1981; 199: 565-571 (Pubitemid 12190968)
44. Pootrakul P, Josephson B, Huebers HA et al. Quantitation of ferritin iron in plasma, an explanation for non-Transferrin iron. Blood 1988; 71: 1120-1123
45. Worwood M, Dawkins S,WagstaffMet al. The purification and properties of ferritin from human serum. Biochem J 1976; 157: 97-103
46. Watanabe K, Muranishi N, Murata Y et al. Biochemical properties of canine serum ferritin: Iron content and nonbinding to concanavalin A. Biometals 2000; 13: 319-324 (Pubitemid 32165261)
47. Kakuta K, Orino K, Yamamoto S et al. High levels of ferritin and its iron in fetal bovine serum. Comp Biochem Physiol A Physiol 1997; 118A: 165-169 (Pubitemid 27319811)
48. Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098 (Pubitemid 38251085)
49. Cecchin E, De Marchi S, Querin F et al. Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis. Kidney Int 1990; 37: 943-950 (Pubitemid 20089227)